T1	Participants 110 166	heart failure patients with preserved ejection fraction.
T2	Participants 273 336	heart failure patients with preserved ejection fraction (HFpEF)
T3	Participants 444 495	chronic outstanding and stable patients with HFpEF.
T4	Participants 516 605	All patients underwent an echocardiogram and radioisotopic ventriculography rest/exercise
T5	Participants 658 734	L-arginine group (n = 15; 8 g/day); and the citrulline malate group (n = 15;
T6	Participants 1329 1362	citrulline to patients with HFpEF
